Sort
82,697 grants matching “vaccine development”
San Francisco Bay Clinical Trials Unit (CTU)
$1,511,389Susan Buchbinder · Public Health Foundation Enterprises · UM1 · FY2022 · AI
Conjugate Anthrax Vaccine with Dual Virulence Factor Specificity
$1,510,824Lallan Giri · Biologics Resources, Llc · R01 · FY2015 · AI
Multi-Omics Analysis of Broadly Neutralizing Antibodies and Therapeutic Vaccination
$1,510,625Dan H. Barouch · Beth Israel Deaconess Medical Center · P01 · FY2024 · AI
Model Development, Data Analysis, and Simulation for Affinity Maturation
$1,510,588Thomas B Kepler · Boston University Medical Campus · U19 · FY2018 · AI
The connection of innate and adaptive anti-cancer immunity
$1,510,560John Greiner · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
BLOOD GROUP ANTIGENS IN HEALTH AND DISEASE
$1,510,407New York Blood Center · P50 · FY2005 · HL
Targeting Feedback Circuitry for Antiviral Therapy
$1,510,374Leor S Weinberger · Autonomous Therapeutics, Inc. · R01 · FY2025 · AI
American and Asian Centers for Arboviral Research and Enhanced Surveillance (A2CARES)
$1,509,842Eva Harris · University Of California Berkeley · U01 · FY2024 · AI
Immune Regulation in Mycobacterial and Fungal Infections
$1,509,737Daniel Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Laboratory And Pre-clinical Studies Of Parainfluenza Viruses
$1,509,699Brian Murphy · Niaid Extramural Activities · Z01 · FY2007 · AI
Task A80: Advanced Small Animal Models for the Testing of Candidate Interventions against Mycobacteria
$1,509,378Angelo Izzo · Colorado State University · N01 · FY2017 · AI
Population-based Approach to Malaria Research and Control
$1,509,165Donald J. Krogstad · Tulane University Of Louisiana · U19 · FY2012 · AI
CIVIC: VACCINE MANUFACTURING AND TOXICOLOGY CORE FOR SARS-CoV-2
$1,509,136Thomas Denny · Duke University · N01 · FY2023 · AI
Molecular Biology Of Retroviruses Associated With AIDS
$1,509,083Malcolm Martin · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
Cultivation, Nature, Ecology and Pathogenicity of the Uncultivable Oral Microbiom
$1,508,903Floyd E Dewhirst · Ada Forsyth Institute, Inc. · R01 · FY2014 · DE
RNA TRASFECTED DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY
$1,508,679Duke University · P01 · FY2001 · CA
Laboratory Studies of Human Respiratory Syncytial Virus and Other Pneumoviruses
$1,507,995Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
Clinical Research Support for the CCR
$1,507,855Thomas A Misteli · Division Of Basic Sciences - Nci · ZID · FY2019 · CA
Structural Characterization of Coronavirus Antibodies Raised by Infection and Vaccination
$1,507,637Pamela J Bjorkman · Rockefeller University · P01 · FY2022 · AI
Unleashing T-cell anti-tumor response through repair of altered RNA splicing and antigen mimicry recognition
$1,507,500Luisa Escobar Hoyos · Yale University · DP2 · FY2022 · CA
Immunotherapy for Malignant Mesothelioma, Lung Cancer and Thymic Malignancies
$1,506,569Raffit Hassan · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
COMBINATORIAL APPROACHES TO TREAT NEOPLASTIC DISEASES
$1,506,546Torrey Pines Inst For Molecular Studies · P01 · FY2002 · CA
Production of Pedigreed SPF Rhesus Macaques
$1,506,427Nicholas W Lerche · University Of California At Davis · U42 · FY2008 · RR
Innate Immune Antivirals for Biodefense
$1,506,330Michael J Gale · University Of Washington · R01 · FY2012 · AI
Vaccines and Therapeutics for Anthrax
$1,506,327Stephen Leppla · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI